How to Treat Hyperviscosity Syndrome

Viscosity of the blood—often colloquially referred to as “thick blood”—is not a formal medical diagnosis but rather a descriptive term that may reflect underlying pathophysiological states such as hyperviscosity syndrome, polycythemia, thrombocytosis, or dyslipidemia. Elevated blood viscosity can impair microcirculatory flow, increase shear stress on vessel walls, and elevate thrombotic risk. Management is never directed at “thinning” blood in isolation; instead, clinicians identify and treat the root cause.

First-line evaluation includes a comprehensive history and physical examination, followed by targeted laboratory testing: complete blood count with differential, peripheral blood smear, serum protein electrophoresis (to screen for paraproteinemias), fasting lipid panel, glucose and HbA1c, renal and hepatic function tests, and inflammatory markers such as C-reactive protein or erythrocyte sedimentation rate. In select cases—particularly when symptoms like headache, visual disturbances, dizziness, or mucosal bleeding are present—quantitative measurement of whole blood viscosity via rotational viscometry may be warranted.

Treatment is etiology-specific. For secondary causes—such as dehydration, smoking, obesity, or uncontrolled hypertension—lifestyle interventions form the cornerstone: adequate hydration, smoking cessation, weight optimization, and rigorous cardiovascular risk factor control. In polycythemia vera, phlebotomy remains first-line therapy to maintain hematocrit below 45%, often supplemented with low-dose aspirin and, in high-risk patients, cytoreductive agents like hydroxyurea. Patients with monoclonal gammopathy—especially IgM-related Waldenström macroglobulinemia—may require plasma exchange (plasmapheresis) acutely for symptomatic hyperviscosity, followed by rituximab-based regimens or BTK inhibitors.

Anticoagulants and antiplatelet agents—including warfarin, direct oral anticoagulants (DOACs), or aspirin—are prescribed only when evidence-based indications exist (e.g., atrial fibrillation, prior venous thromboembolism, or established arterial disease), not solely based on perceived blood thickness. Unwarranted use of these agents carries significant hemorrhagic risk without proven benefit in asymptomatic individuals with isolated viscosity concerns.

Patients should be counseled that “blood thinners” do not alter intrinsic blood viscosity; rather, they modulate coagulation pathways or platelet function. True viscosity reduction depends on correcting hematologic parameters, plasma protein composition, or rheologic properties through precise, diagnosis-driven therapy. Ongoing monitoring and multidisciplinary collaboration—between primary care, hematology, and cardiology—are essential for safe, effective management.